Brief: Aslan Pharmaceuticals Acquires Full Global Commercial Rights For ASLAN004 From CSL

Aslan Pharmaceuticals

31/05/2019 08:27

May 31 (Reuters) - Aslan Pharmaceuticals:
    * ASLAN PHARMACEUTICALS ACQUIRES FULL GLOBAL COMMERCIAL
RIGHTS FOR
ASLAN004 FROM CSL
    * ASLAN PHARMACEUTICALS-AMENDED LICENSE AGREEMENT WITH CSL
SO CO
HAS FULL GLOBAL RIGHTS TO DEVELOP, MANUFACTURE .COMMERCIALISE
ASLAN004 IN ALL INDICATIONS
    * ASLAN PHARMACEUTICALS LTD SAYS AMENDED AGREEMENT REPLACES
LICENSING AGREEMENT ASLAN AND CSL SIGNED IN MAY 2014
    * ASLAN PHARMACEUTICALS-UNDER TERMS OF AMENDED AGREEMENT, CO
TO
MAKE FIRST PAYMENT OF US$30 MILLION TO CSL UPON COMMENCEMENT OF
A PHASE 3 STUDY OF ASLAN004
    * ASLAN PHARMACEUTICALS - CSL IS ALSO ELIGIBLE TO RECEIVE UP
TO
US$95 MILLION OF REGULATORY MILESTONES
    * ASLAN PHARMACEUTICALS - CSL IS ALSO ELIGIBLE TO RECEIVE
$655
MILLION OF SALES MILESTONES, TIERED ROYALTIES ON NET SALES
BETWEEN MID-SINGLE DIGITS AND 10%

Source text for Eikon:  ID:nGNX6fSNkb 
Further company coverage:  6497.TWO 

 ((Reuters.Briefs@thomsonreuters.com;))